Solifenacin succinate

Drug #2248

Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.

← Previous drug Next drug →

Primary Characteristics

It belongs to Isoquinoline Butane Dioic Acid.

It belongs to Cholinergic muscarinic antagonist pharmacological group on the basis of mechanism of action.

Molecular Weight: 480.5 · Solubility in Water: freely soluble · Non-proprietary name: Solifenacin succinate.

Molecular structure of Solifenacin succinate

Pharmacokinetics

Absorption: Solifenacin succinate has an oral bioavailability is 90%.

Distribution: Solifenacin succinate has a volume of distribution is 600L. plasma protein binding is 98%.

Elimination: it is metabolised via mainly by CYP3A4 in liver, plasma half-life is 45-68 hours, renal excretion is 69.2%.

Indications

Solifenacin succinate is primarily indicated in conditions like Urinary frequency and incontinence.

Contraindications

Solifenacin succinate is contraindicated in conditions like Narrow-angle glaucoma, Urinary retention, Urinary retention, Gastric retention, Hypersensitivity to any component of product.

Dosage

Solifenacin succinate's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
7.5 mg	7.5 mg	Every 24h	PO	It can be administered with or without food. In patients with sever renal impairment (CLcr < 30 ml/min) and moderate hepatic impairment; greater than 5 mg/day dose is not recommended. It should not be taken in case of sever hepatic impairment.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Solifenacin succinate in overdosage may give rise to further complications which include Intestinal obstruction , Respiratory depression , Angioneurotic edema.

The signs and symptoms that are produced after acute overdosage of Solifenacin succinate are Tachycardia , Mydriasis, Photophobia, Respiratory depression, Memory disturbance, Agitation, Ataxia, Confusion , Euphoria , Angioedema, Peripheral edema, Tremor, Blurred vision, Dry mouth, Respiratory depression, Disorientation , Vomiting, Urinary retention, Dry skin.

Solifenacin succinate is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Blurred vision, Constipation , Dizziness, Dry eye, Dry mouth, Dyspepsia , Headache, Nausea, Peripheral edema, Urinary retention, Vomiting .

Warnings / Precautions

Incase of angioedema, if involvement of the tongue, hypopharynx, or larynx occurs, solifenacin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided. Administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention. Use with caution in patients with decreased gastrointestinal motility, narrow-angle glaucoma, reduced renal function, reduced hepatic function. Its doses greater than 5 mg are not recommended in patients with severe renal impairment (CLcr <30 mL/min) and moderate hepatic impairment. while, it is not recommended for patients with severe hepatic impairment. It should not be administered during nursing. The safety and effectiveness in pediatric patients have not been established.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs

10 mg 5 mg

Storage Conditions

Solifenacin succinate should be stored Tablet.

Drug Classification

1.29 — Drugs used in renal, bladder, and prostatic disorders

Manufacturers

Manufacturers of Solifenacin succinate in Pakistan:

Efroze Getz Helix Highnoon Ray